Deuruxolitinib, sold under the brand name Leqselvi, is a medication used for the treatment of alopecia areata.

[2] Although the relative effectiveness of deuruxolitinib and another Janus kinase inhibitor—baricitinib—for alopecia areata may vary depending on the population studied, both drugs are more effective than alternative treatments.

[3] Deuruxolitinib was approved for medical use in the United States in July 2024.

[1] The FDA prescribing label for deuruxolitinib contains a boxed warning for serious infections; malignancies; cardiovascular death, myocardial infarction, and stroke; and thrombosis.

[6] Deuruxolitinib was approved for medical use in the United States in July 2024.